KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non Operating Income (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Non Operating Income for 11 consecutive years, with $24.8 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 11.48% to $24.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.6 million through Dec 2025, down 16.64% year-over-year, with the annual reading at $86.6 million for FY2025, 16.65% down from the prior year.
  • Non Operating Income hit $24.8 million in Q4 2025 for CRISPR Therapeutics AG, down from $26.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $28.0 million in Q4 2024 to a low of $363000.0 in Q1 2022.
  • Historically, Non Operating Income has averaged $14.5 million across 5 years, with a median of $16.0 million in 2023.
  • Biggest five-year swings in Non Operating Income: plummeted 81.43% in 2022 and later surged 3410.19% in 2023.
  • Year by year, Non Operating Income stood at $2.2 million in 2021, then soared by 422.99% to $11.5 million in 2022, then surged by 74.04% to $20.0 million in 2023, then soared by 39.91% to $28.0 million in 2024, then fell by 11.48% to $24.8 million in 2025.
  • Business Quant data shows Non Operating Income for CRSP at $24.8 million in Q4 2025, $26.2 million in Q3 2025, and $22.1 million in Q2 2025.